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Summary
Background.— Pericardial effusion (PE) can occur during or after atrial ﬁbrillation (AF) ablation,
and may induce atrial arrhythmia.
Aim.— To characterize the impact of PE on arrhythmia recurrences following AF ablation.
Methods.— Patients referred for a ﬁrst radiofrequency AF ablation were studied prospectively.
Transthoracic echocardiography was performed before and 24 h after the procedure. If PE was
present, transthoracic echocardiography was repeated at 1month to evaluate PE evolution.
Early arrhythmia recurrences (EARs) were deﬁned as any arrhythmia documented within 1month
of the procedure.
Results.— PE was diagnosed in 18/81 patients (22%); and was present in signiﬁcantly more
patients with persistent versus paroxysmal AF (14/40 [35%] vs 4/41 [10%]; P = 0.008). PEs were
mild (mean 6± 3mm), mainly asymptomatic (89%), and none required pericardiocentesis. Early
and late arrhythmia recurrences were present in 25/81 (31%) and 29/81 (36%), respectively. The
incidence of PE was signiﬁcantly higher among patients with EARs versus those without (12/25
[48%] vs 6/56 [11%]; P = 0.0004). By multivariable analysis, PE and duration in AF were the two
Abbreviations: AF, atrial ﬁbrillation; EAR, early arrhythmia recurrence; ECG, electrocardiogram; IQR, interquartile range; LA, left
atrium; LVEF, left ventricular ejection fraction; PE, pericardial effusion; TTE, transthoracic echocardiography.
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independent predictors of EARs. PE incidence was similar in patients with and without late
arrhythmia recurrences. At 1month, no patients had PE on transthoracic echocardiography.
Conclusion.— PE following radiofrequency AF ablation is frequent, particularly following per-
sistent AF ablation. This effusion is generally mild, mainly asymptomatic, and independently
associated with EARs.
© 2011 Elsevier Masson SAS. All rights reserved.
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Résumé
Contexte.— Un épanchement péricardique peut survenir pendant ou après la réalisation d’une
ablation de ﬁbrillation atriale et peut induire des arythmies atriales.
Objectifs.— Pour caractériser les épanchements péricardiques survenant après cette interven-
tion et d’étudier leur relation avec la survenue d’arythmie postablation.
Méthodes.— Nous avons étudié de manière prospective des patients adressés dans notre cen-
tre pour ablation de ﬁbrillation atriale. Une échocardiographie transthoracique a été réalisée
avant et 24 heures après l’intervention. Une récidive d’arythmie précoce était déﬁnie par une
arythmie atriale documentée dans le mois suivant l’ablation. Quatre-vingts un patients ont été
inclus dans cette étude.
Résultats.— Un épanchement péricardique a été diagnostiqué dans 22 % des cas et plus
particulièrement 35% des patients avec ﬁbrillation atriale persistante et 10 % paroxystique
(p = 0,008). Ces épanchements péricardiques étaient le plus souvent modérées (6± 3mm),
asymptomatiques (89 %) et aucun n’a nécessité de drainage. Des récidives d’arythmie précoce
et tardive étaient présentes chez 31 et 36 % respectivement dans notre population. L’incidence
d’épanchement péricardique était plus élevée chez les patients présentant une récidive précoce
d’arythmie comparé aux patients n’ayant pas de récidive précoce (48 % versus 11 %, p = 0,0004).
En analyse multivariée, la présence d’un épanchement péricardique et l’ancienneté de la ﬁb-
rillation atriale étaient les deux seuls facteurs prédictifs indépendants de récidive d’arythmie
précoce. L’incidence d’épanchement péricardique était identique chez les patients présen-
tant une récidive tardive d’arythmie ou non. Aucun de nos patients n’avait d’épanchement
péricardique unmois après l’intervention.
Conclusion.— Un épanchement péricardique est fréquemment rencontré après ablation de ﬁb-
rillation atriale avec radiofréquence surtout après ablation de ﬁbrillation atriale persistante.
Ces épanchements sont modérés, le plus souvent asymptomatiques et associés de manière
indépendante à la survenue d’arythmie précoce postablation.
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Background
Catheter ablation of AF is an established therapy for patients
with both paroxysmal and persistent AF [1,2]. However,
numerous complications have been associated with this pro-
cedure, including PE [3]. It has recently been reported that
PE is common (10—14%) following AF ablation, but is mainly
mild and asymptomatic [4,5].
EARs are common during the ﬁrst month following AF
ablation [6,7]. However, the signiﬁcance of these EARs in
predicting the long-term success of the procedure is contro-
versial [8,9]. Consistent with this, the consensus document
on catheter and surgical ablation of AF has suggested a
uniform ‘blanking period’ of 3months [10]. The pathophys-
iology of these early arrhythmias is also unclear. Transient
autonomic neural modiﬁcations or acute tissue inﬂammation
have been suggested as possible mechanisms [11,12].
We have studied the incidence and characteristics of PE
following paroxysmal and persistent AF ablation. As PE is
known to be a common cause of atrial arrhythmias [13],
we also evaluated the relationship between early and late
arrhythmia recurrences and the occurrence of acute PE fol-
lowing AF ablation.
t
e
a
es droits réservés.
ethods
tudy population
e prospectively studied patients referred to our centre
or a ﬁrst radiofrequency AF ablation between September
008 and January 2010. Patients undergoing paroxysmal AF
blation with cryotherapy were excluded in order to homog-
nize our population, as radiofrequency and cryotherapy
reate different tissue lesions that can inﬂuence arrhythmia
ecurrences after ablation, and also because persistent AF
blation could not be performed with cryotherapy. Patients
ith PE before AF ablation were also excluded. The study
as approved by an institutional review committee, and all
ubjects gave written informed consent.
chocardiography data
omprehensive echocardiography examination including
ransoesophageal echocardiography before AF ablation to
xclude left appendage thrombus and standard TTE before
nd 24 h after AF ablation procedure were performed for
ach patient, with a particular focus on the presence of
4a
S
o
s
c
M
p
A
w
t
b
E
A
g
b
e
b
2
h
f
f
q
P
s
i
m
C
s
c
s
a
u
o
[
1
r
a
c
a
t
w
s
A
ﬁ
R
i
B
T
e
e
d
a
w
a
a
c
I
a
w
p
F
P
w
i
f
t
t
c
a
p
d
a
O
i
a
p
a
1
D
R
a
T
A
a
a
a
d
S
C
m
t
a
t
b
F
w
t
t
c
R52
new PE. Left ventricular function was assessed by the
impson biplane method and LA diameter was measured
n the parasternal long-axis view. PE was assessed from
tandard TTE using parasternal long-axis, short-axis and sub-
ostal views, and was quantiﬁed during diastolic timing using
mode on the posterior wall. To differentiate PE from
ericardial fat, echocardiography data before and after
F were compared. The diagnosis of epicardial fat tissue
as retained if the echo-free space was located anteriorly,
ended to move in concert with the heart, and remained sta-
le compared to echocardiography data before AF ablation.
lectrophysiological study
ll patients received effective anticoagulation therapy (tar-
et international normalized ratio 2—3) for at least 1month
efore AF ablation. All antiarrhythmic drugs, with the
xception of amiodarone, were discontinued ﬁve half-lives
efore the procedure. Oral anticoagulation was stopped
days before the procedure, and low-molecular-weight
eparin was started. The electrophysiological study was per-
ormed under conscious sedation using remifentanyl.
The following catheters were introduced via the right
emoral vein for electrophysiological study: (i) a steerable
uadripolar or decapolar catheter (Xtrem; Ela Medical, Le
lessis-Robinson, France) was positioned within the coronary
inus, positioned at 4—5 o’clock along the mitral annulus
n a left anterior oblique projection; (ii) a circumferential
apping catheter (Lasso; Biosense Webster, Diamond Bar,
A, USA) was introduced following transseptal access and
tabilized using a long sheath (SL0 sheath; St Jude Medi-
al, Sylmar, CA, USA) continuously perfused with heparinized
aline solution; and (iii) a 3.5mm externally irrigated tip
blation catheter (Celsius Thermocool; Biosense Webster)
sed for mapping and ablation.
Transseptal puncture was performed with the guidance
f intracardiac echocardiography used transoesophageally
14]. Following transseptal access, a single bolus of
00 IU/kg body weight of heparin was administrated and
epeated if activated clotting time was < 300ms.
Monitoring with a surface electrocardiogram (ECG)
nd bipolar endocardial electrogram was carried out
ontinuously and recorded on a computer-based digital
mpliﬁer/recorder system for off-line analysis (Bard Elec-
rophysiology, Lowell, MA, USA). Intracardiac electrograms
ere ﬁltered from 30—500Hz and measured at a sweep
peed of 100mm/s.
blation of paroxysmal and persistent atrial
brillation
adiofrequency energy was delivered at up to 35W using an
rrigation rate of ≥ 20mL/min (0.9% saline via Cool Flow;
iosense-Webster) to achieve the desired power delivery.
emperature was limited to 45 ◦C.
For paroxysmal AF ablation, the procedure was consid-
red successful when all the pulmonary veins were isolated
lectrically. If a patient experienced AF during the proce-
ure, AF ablation was continued until termination of AF was
chieved as described for persistent AF ablation.
Ablation of persistent or long-lasting persistent AF
as performed sequentially as described previously [15],
S
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nd involved pulmonary vein isolation, electrogram-based
blation, and linear ablation, with termination of AF via
atheter ablation being the endpoint (stepwise approach).
f the patient converted into atrial tachycardia, this
rrhythmia was mapped and ablated until sinus rhythm
as restored. Finally, if patient was still in AF after 5 h of
rocedure, an external cardioversion was performed.
ollow-up
atients were followed at 1month and then every 3months
ith systematic 12-lead ECG and 24-hour Holter monitor-
ng in our centre for 1 year. They also underwent routine
ollow-up by their referring cardiologist. From 1 year after
he last procedure, they were followed every 6months by
heir referring cardiologist.
All patients had antiarrhythmic therapies, including ﬂe-
ainide and beta-blockers for 1month (for paroxysmal AF)
nd amiodarone for 3months (for persistent or long-lasting
ersistent AF). If arrhythmia recurred after stopping these
rugs, antiarrhythmic therapies were restarted. Further
blation was performed if arrhythmias were still present.
ral anticoagulation treatment was restarted 1 day follow-
ng the procedure, and was continued for at least 3months.
Patients with PE following AF ablation systematically had
nother TTE to study PE evolution 1month after the index
rocedure. Patients with signiﬁcant pericarditis pain associ-
ted with PE had non-steroidal anti-inﬂammatory drugs for
month.
eﬁnition of early and late arrhythmias
ecurrences were deﬁned as documented atrial arrhythmias
fter the index AF ablation that lasted for ≥ 3minutes [16].
he arrhythmia recurrences were characterized as follows:
F deﬁned as chaotic and uncoordinated activity of the
trium [10] and atrial tachycardia deﬁned as a monomorphic
trial activity on 12-lead surface ECG. EARs were deﬁned as
ny arrhythmia documented within 1month of the proce-
ure.
tatistical analysis
ontinuous variables are expressed as mean± SD, or
edian± interquartile range [IQR] when variables appeared
o be non-normally distributed. Statistical signiﬁcance was
ssessed using the unpaired Student’s t test or Mann-Whitney
est, if necessary. Categorical variables, expressed as num-
ers or percentages, were analysed with the Chi2 test or
isher’s exact test. Univariate factors presenting P < 0.1
ere analysed using a logistic regression method for mul-
ivariable analysis (performed with StatView Software). All
ests were two-tailed and P < 0.05 was considered statisti-
ally signiﬁcant.
esultstudy population
total of 98 consecutive patients were referred for a ﬁrst
F ablation from September 2008 to January 2010. Among
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Table 1 Characteristics of all patients, and of those with paroxysmal or persistent atrial ﬁbrillation (AF).
All patients (n = 81) Paroxysmal AF (n = 41) Persistent AF (n = 40) p
Male 57 (70) 28 (68) 29 (72) 0.67
Age (years) 56± 11 56± 12 56± 11 0.99
Hypertension 34 (42) 18 (44) 16 (40) 0.72
Diabetes 8 (10) 4 (10) 4 (10) 0.97
Hypercholesterolaemia 27 (33) 12 (29) 15 (37) 0.43
History of AF (months) 64± 66 66± 79 61± 49 0.76
Structural heart disease 31 (38) 12 (29) 19 (48) 0.09
Ischaemic cardiomyopathy 8 (10) 2 (5) 6 (15) 0.13
LVEF (%) 55± 10 58± 7 52± 12 0.01
LA diameter (mm) 43± 5 42± 6 44± 5 0.31
Beta-blockers 42 (52) 18 (44) 24 (60) 0.14
Amiodarone 30 (37) 13 (32) 17 (42) 0.32
Oral anticoagulation 75 (93) 37 (90) 38 (95) 0.41
Antiplatelet therapy 19 (23) 14 (34) 5 (12) 0.02
Radiofrequency time (min) 70± 36 48± 26 92± 30 < 0.0001
Fluoroscopy time (min) 75± 25 62± 21 88± 22 0.007
Data are mean± standard deviation or number (%). AF: atrial ﬁbrillation; LA: left atrium; LVEF: left ventricular ejection fraction.
these, 17 underwent cryoablation for paroxysmal AF and
were therefore excluded from our analysis. No patients had
PE on TTE before AF ablation. Therefore, 81 patients were
included in the analysis. For each patient, only the ﬁrst pro-
cedure was analysed in this study. The median follow-up for
our population was 8 (range 6—23) months. Four patients
were lost during our long-term follow-up.
Table 1 describes the characteristics of the total study
population, as well as in patients with paroxysmal AF (n = 41)
or persistent AF (n = 40; including 15 with long-lasting per-
sistent AF).
Patients with paroxysmal versus persistent AF ablation
had signiﬁcantly higher left ventricular ejection fraction
(LVEF) (58± 7% vs 52± 12%; P = 0.01); a higher rate of
antiplatelet therapy (34% vs 12%; P = 0.02); and shorter
radiofrequency time (48± 26 vs 92± 30min; P < 0.0001).
Characteristics of pericardial effusions
Following AF ablation, 18 patients (22%) exhibited PE,
detected by TTE. The characteristics of the PEs in these
patients are shown in Table 2. Only two of the 18 patients
Table 2 Characteristics of pericardial effusions.
Pericardial
effusions (n = 18)
Dimension (mm) 6± 3
Location
Posterior left ventricle 9 (50)
Posterior right ventricle 6 (33)
Right atrium 2 (11)
Circumferential 1 (6)
Data are mean± standard deviation or number (%).
(11%) complained of pericarditis pain associated with PE,
and they were treated with non-steroidal anti-inﬂammatory
drugs. None of these patients had tamponade or required
surgical evacuation. In all of these patients, PE was self-
limiting, as none of the patients had PE on TTE performed
1month after the index procedure.
Characteristics of patients with or without
pericardial effusion
As shown in Table 3, patients with PE had a signiﬁcantly
longer duration in AF before ablation (P = 0.002) and they
experienced a longer duration of radiofrequency during the
index procedure (P = 0.002). Interestingly, as shown in Fig. 1,
the rate of PE was signiﬁcantly higher following AF ablation
in patients with persistent AF versus paroxysmal AF (35% vs
10%; P = 0.008).
Figure 1. Incidence of PE occurring during the 24 h following AF
ablation among patients with paroxysmal or persistent AF. AF: atrial
ﬁbrillation; PE: pericardial effusion.
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Table 3 Characteristics of patients with or without pericardial effusion.
Patients with PE (n = 18) Patients without PE (n = 63) pa
Male sex 10 (56) 47 (75) 0.14
Age (years) 60± 12 56± 16 0.78
Hypertension 7 (39) 27 (43) 0.79
Diabetes 1 (6) 7 (11) 0.68
Hypercholesterolaemia 9 (50) 18 (29) 0.10
Persistent AF 14 (78) 26 (41) 0.008
Duration in AF (months) 7± 26 1± 6 0.002
Structural heart disease 7 (38) 24 (38) 0.99
Ischaemic cardiomyopathy 0 8 (13) 0.19
LVEF (%) 60± 10 60± 5 0.90
LA diameter (mm) 43± 5 44± 7 0.84
Beta-blockers 10 (56) 32 (51) 0.79
Amiodarone 8 (44) 22 (35) 0.58
Oral anticoagulation 17 (94) 58 (92) 0.99
Antiplatelet therapy 2 (11) 17 (27) 0.22
Radiofrequency time (min) 93± 27 54± 50 0.002
Data are median± interquartile range or number (%). AF: atrial ﬁbrillation; LA: left atrium; LVEF: left ventricular ejection fraction; PE:
pericardial effusion.
a Mann-Whitney test and Fisher’s exact test were used to compare continuous variables and nominal variables, respectively.
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rrhythmia recurrences
n our population, 25 patients (31%) experienced EAR and
9 patients (36%) had late arrhythmia recurrences. Among
atients experiencing EAR, 14/25 (56%) had AF, and 11/25
44%) had atrial tachycardia. The characteristics of patients
ith or without EAR are described in Table 4. Most base-
ine characteristics were not signiﬁcantly different between
hese two groups. However, patients with EAR had a signiﬁ-
antly longer duration in AF before AF ablation compared to
hose without EAR (P < 0.0001). Additionally, patients with
AR had a higher prevalence of persistent AF (76% vs 38%;
= 0.002). Moreover, radiofrequency time was signiﬁcantly
onger in patients with versus without EAR (P = 0.0009).
As shown in Fig. 2A, the rate of PE was signiﬁcantly
igher among patients with EAR compared to those without
48% vs 11%; P = 0.0004). However, the rate of PE was simi-
ar in patients with or without late arrhythmia recurrences
Fig. 2B).
ultivariable analysis
ultivariable analysis showed that occurrence of PE and
uration in AF were independent predictors of EAR (Table 5).
edo ablationsnly 15 patients underwent a redo AF ablation. Among
hese, three (20%) developed a PE. Interestingly, these three
atients also experienced PE after their ﬁrst AF ablation
rocedure.
Figure 2. Comparison of PE incidence occurring during the 24 h
after AF ablation in patients with or without early (A) or late (B)
arrhythmia recurrences. AF: atrial ﬁbrillation; PE: pericardial effu-
sion.
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Table 4 Characteristics of patients with or without early arrhythmia recurrence (EARs).
Patients with EAR (n = 25) Patients without EAR (n = 56) pa
Male sex 16 (64) 41 (73) 0.44
Age (years) 60± 12 57± 17 0.37
Hypertension 11 (44) 23 (41) 0.81
Diabetes 3 (12) 5 (9) 0.70
Hypercholesterolaemia 11 (44) 16 (29) 0.21
Persistent AF 76 3 0.002
Duration in AF (months) 13± 33 1± 4 < 0.0001
Structural heart disease 6 (24) 25 (45) 0.09
Ischaemic cardiomyopathy 2 (8) 6 (11) 0.99
LVEF (%) 60± 4 60± 6 0.79
LA diameter (mm) 43± 5 45± 8 0.86
Beta-blockers 15 (60) 27 (48) 0.35
Amiodarone 7 (28) 23 (41) 0.32
Oral anticoagulation 24 (95) 51 (91) 0.66
Antiplatelet therapy 4 (16) 15 (27) 0.40
Radiofrequency time (min) 98± 46 53± 45 0.0009
Data are median± interquartile range or number (%). AF: atrial ﬁbrillation; LA: left atrium; LVEF: left ventricular ejection fraction; PE:
pericardial effusion.
a Mann-Whitney test and Fisher’s exact test were used to compare con
Discussion
In our study, PE following AF ablation occurred in 22% of
patients, and was more common following persistent than
paroxysmal AF ablation (35% vs 10%). We also found that PE
was independently associated with the occurrence of EAR
after AF ablation, but was not related to late arrhythmia
recurrences. Fortunately, the PEs in our study were mild,
mainly asymptomatic, never required surgical evacuation,
and always resolved within 1month of the index procedure.
However, some patients can suffer major PE after
AF ablation, resulting in cardiac tamponade that usually
requires pericardiocentesis. Tamponade is considered to
be one of the potentially life-threatening complications
associated with AF ablation. Usually, cardiac tamponade
happens during AF ablation and is associated with traumatic
transseptal puncture. In a large, prospective study, Bertaglia
et al. reported that 0.6% of 1011 patients had tamponade
during AF ablation that was successfully treated with peri-
cardiocentesis [3]. A similar rate (0.8%) was reported by
Pappone et al. among 251 patients undergoing AF ablation
[17]. Likewise, Chierchia et al. reported that 1.5% of 133
patients undergoing AF ablation with either radiofrequency
or cryotherapy had cardiac tamponade [4]; and Chen et al.
Table 5 Multivariable analysis of predictors of early
arrhythmia recurrence (EAR).
Odds ratio 95% CI p
Duration of AF 1.045 1.001 ± 1.085 0.04
Persistent AF 0.864 0.182 ± 4.053 0.84
Pericardial effusion 3.466 1.001 ± 14.22 0.04
Radiofrequency time 1.024 0.999 ± 1.042 0.06
AF: atrial ﬁbrillation; CI: conﬁdence interval.
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ound that tamponade occurred in 0.6% of 156 patients fol-
owing AF ablation [5].
Contrary to acute tamponade, minor PEs are mainly
symptomatic and do not require pericardiocentesis. In the
tudies by Bertaglia et al. and Pappone et al., the rate of
ild PE was 0.8% [3,17]. However, neither of these stud-
es speciﬁcally looked for PE, and as such would not have
ecorded mild, asymptomatic PEs. In two studies that did
peciﬁcally look for PE, as we did in our study, the rate of
inor PE was much higher. In the study by Chierchia et al.,
2% of patients had a minor PE, and 0.8%, a moderate PE
4]. Consistent with this, Chen et al. found mild PE in 10%
f 156 patients following AF ablation [5]. In our study, 22%
f patients had PE following AF ablation, which is somewhat
igher than previously described. The discrepancy between
he PE rate in our study and those in the former studies
ould be due to the fact that our rate of persistent AF abla-
ion (49%) was much higher than in the previous studies (0%
4] and 27% [5]). We also found that PE occurred more fre-
uently after persistent AF ablation, possibly due to longer
adiofrequency time.
The pathophysiology of mild PEs following AF abla-
ion is unknown. However, histopathological evidence of
yocardial damage, including important local inﬂamma-
ory responses following radiofrequency ablation, has been
emonstrated in animal models [18] and human hearts [19].
herefore, one possible mechanism could be a pericarditis
ue to local tissue inﬂammation secondary to radiofre-
uency. Moreover, AF ablation is associated with systemic
nﬂammation activation [20,21] that could also explain
he occurrence of pericarditis following AF ablation. Also,
trium trauma secondary to extensive biatrial radiofre-
uency ablation or catheter manipulation by itself could
ause mild pericardial haemorrhage. As none of our patients
ad pericardial evacuation, we could not analyse the char-
cteristics of the effusion in our population.
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The clinical signiﬁcance of mild PEs on arrhythmia recur-
ences following AF ablation has not, to the best of our
nowledge, been speciﬁcally evaluated in previous studies.
he deﬁnition of early recurrences following AF ablation
aries in the literature depending on the timing and the
ype of arrhythmia documented after the ﬁrst AF abla-
ion procedure. Oral et al. deﬁned EAR as a sustained
pisode of AF within 15 days of the procedure [8]. How-
ver, Lee et al. deﬁned EAR as a sustained episode of
F within 1month of the procedure [9], while O’Donnell
t al. deﬁned EAR as a recurrence of AF within 3months
f the ablation procedure [22]. Since the optimal time
imit to deﬁne EAR has not been speciﬁcally established,
n this study, arrhythmia recurrences were considered to
e early if they occurred within 1month of the index pro-
edure, as has been used in other studies [9,23]. This
s thought to correspond with an unstable state due to
he initial inﬂammatory process following the ablation
18,23].
In our study, the EAR rate was 31%. This is consistent with
revious studies that have reported that 13—50% of patients
ave EAR following paroxysmal or persistent AF ablation
8,9,24]. However, the clinical signiﬁcance of EAR is contro-
ersial [8,9,24]. Many investigators consider that EAR should
e treated by antiarrhythmic drugs until a stable atrial tis-
ue state is present [8,25]. Consistent with this, the recent
onsensus document on catheter and surgical ablation of
F has suggested a uniform ‘blanking period’ of 3months
10].
The pathophysiology of EAR after AF ablation has not
een elucidated. However, multiple hypotheses have been
uggested, such as LA oedema following radiofrequency
issue lesion that could lead to alterations in conduction
elocity [26—28]. Moreover, AF ablation can modify the auto-
omic nervous system, leading to an increased risk of atrial
rrhythmias [11,12].
Additionally, some patients with EAR will not experience
ate recurrences. Therefore, some investigators have sug-
ested that a delayed beneﬁcial effect of radiofrequency
blation, secondary to scar consolidation, may explain this
henomenon [29—31]. In our study, 48% of patients with
AR experienced PE immediately after AF ablation. We also
ound that PE was independently associated with EAR. We
herefore hypothesize that mild PE could be a signiﬁcant
arker of pericardial irritation leading to EAR.
Most of our patients with PE were asymptomatic; and
he two patients who developed pericarditis-like chest pain
ere treated with non-steroidal anti-inﬂammatory drugs.
owever, due to the small number of patients, we could
ot analyse the effect of non-steroidal anti-inﬂammatory
rugs in this population on mid- or long-term clinical out-
ome after AF ablation. Recently, Koyama et al. showed
hat corticosteroids administered 3 days after AF ablation
ould decreased the occurrence of EAR [32]. Although the
ain mechanism suspected by the authors was a decrease
n atrial tissue proarrhythmogenic inﬂammation, another
xplanation could be a direct effect of corticosteroids on
E.Finally, we could hypothesize that cardioversion in
atients experiencing acute PE and EAR following AF abla-
ion may be postponed until PE resolution. However, larger
tudies are required to conﬁrm this interesting hypothesis.N. Lellouche et al.
imitations
his was a single-centre study, and our results need conﬁr-
ation in a larger population of patients. In our study, the
verall clinical success may have been overestimated due
o some undiagnosed episodes of asymptomatic arrhythmia.
oreover, we did not assess systemic inﬂammatory activa-
ion, such as C-reactive protein measurement, to correlate
hese markers with PE occurrence. Finally, the effect of
rugs on PEs and the impact on future arrhythmias were
ot speciﬁcally studied.
onclusions
E following AF ablation with radiofrequency is frequent,
articularly following persistent AF ablation. In our study
opulation, PE was mild, mainly asymptomatic, and inde-
endently associated with EARs.
isclosure of interest
he authors declare that they have no conﬂicts of interest
oncerning this article.
eferences
[1] Oral H, Pappone C, Chugh A, et al. Circumferential pulmonary-
vein ablation for chronic atrial ﬁbrillation. N Engl J Med
2006;354:934—41.
[2] Haïssaguerre M, Hocini M, Sanders P, et al. Catheter ablation of
long-lasting persistent atrial ﬁbrillation: clinical outcome and
mechanisms of subsequent arrhythmias. J Cardiovasc Electro-
physiol 2005;16:1138—47.
[3] Bertaglia E, Zoppo F, Tondo C, et al. Early complications of
pulmonary vein catheter ablation for atrial ﬁbrillation: a multi-
center prospective registry on procedural safety. Heart Rhythm
2007;4:1265—71.
[4] Chierchia GB, Capulzini L, Droogmans S, et al. Pericardial
effusion in atrial ﬁbrillation ablation: a comparison between
cryoballoon and radiofrequency pulmonary vein isolation.
Europace 2010;12:337—41.
[5] Chen SW, Liu SW, Lin JX. Incidence, risk factors and man-
agement of pericardial effusion post radiofrequency catheter
ablation in patients with atrial ﬁbrillation. Zhonghua Xin Xue
Guan Bing Za Zhi 2008;36:801—6.
[6] Jiang H, Lu Z, Lei H, Zhao D, Yang B, Huang C. Predic-
tors of early recurrence and delayed cure after segmental
pulmonary vein isolation for paroxysmal atrial ﬁbrillation with-
out structural heart disease. J Interv Card Electrophysiol
2006;15:157—63.
[7] Bertaglia E, Stabile G, Senatore G, et al. Predictive value of
early atrial tachyarrhythmias recurrence after circumferential
anatomical pulmonary vein ablation. Pacing Clin Electrophysiol
2005;28:366—71.
[8] Oral H, Knight BP, Ozaydin M, et al. Clinical signiﬁcance of early
recurrences of atrial ﬁbrillation after pulmonary vein isolation.
J Am Coll Cardiol 2002;40:100—4.[9] Lee SH, Tai CT, Hsieh MH, et al. Predictors of early and
late recurrence of atrial ﬁbrillation after catheter ablation
of paroxysmal atrial ﬁbrillation. J Interv Card Electrophysiol
2004;10:221—6.
ablat
[
[
[
[
[
[
[
[
[
[Pericardial effusion and recurrences after atrial ﬁbrillation
[10] Calkins H, Brugada J, Packer DL, et al. HRS/EHRA/ECAS expert
consensus statement on catheter and surgical ablation of atrial
ﬁbrillation: recommendations for personnel, policy, proce-
dures and follow-up. Europace 2007;9:335—79.
[11] Pappone C, Santinelli V, Manguso F, et al. Pulmonary vein
denervation enhances long-term beneﬁt after circumferen-
tial ablation for paroxysmal atrial ﬁbrillation. Circulation
2004;109:327—34.
[12] Hsieh MH, Chiou CW, Wen ZC, et al. Alterations of heart
rate variability after radiofrequency catheter ablation of focal
atrial ﬁbrillation originating from pulmonary veins. Circulation
1999;100:2237—43.
[13] Spodick DH. Frequency of arrhythmias in acute pericarditis
determined by Holter monitoring. Am J Cardiol 1984;53:842—5.
[14] Mitchell-Heggs L, Lellouche N, Deal L, et al. Transseptal punc-
ture using minimally invasive echocardiography during atrial
ﬁbrillation ablation. Europace 2010;12:1435—8.
[15] Takahashi Y, O’Neill MD, Hocini M, et al. Effects of stepwise
ablation of chronic atrial ﬁbrillation on atrial electrical and
mechanical properties. J Am Coll Cardiol 2007;49:1306—14.
[16] Jaïs P, Cauchemez B, Macle L, et al. Catheter ablation ver-
sus antiarrhythmic drugs for atrial ﬁbrillation: the A4 study.
Circulation 2008;118:2498—505.
[17] Pappone C, Oreto G, Rosanio S, et al. Atrial electroanatomic
remodeling after circumferential radiofrequency pulmonary
vein ablation: efﬁcacy of an anatomic approach in a
large cohort of patients with atrial ﬁbrillation. Circulation
2001;104:2539—44.
[18] Tanno K, Kobayashi Y, Kurano K, et al. Histopathology of canine
hearts subjected to catheter ablation using radiofrequency
energy. Jpn Circ J 1994;58:123—35.
[19] Grubman E, Pavri BB, Lyle S, Reynolds C, Denofrio D, Kocovic
DZ. Histopathologic effects of radiofrequency catheter abla-
tion in previously infarcted human myocardium. J Cardiovasc
Electrophysiol 1999;10:336—42.
[20] Weber R, Minners J, Restle C, et al. Pulmonary edema after
extensive radiofrequency ablation for atrial ﬁbrillation. J Car-
diovasc Electrophysiol 2008;19:748—52.
[21] Lellouche N, Sacher F, Wright M, et al. Usefulness of C-reactive
protein in predicting early and late recurrences after atrial
ﬁbrillation ablation. Europace 2009;11:662—4.
[ion 457
22] O’Donnell D, Furniss SS, Dunuwille A, Bourke JP. Delayed cure
despite early recurrence after pulmonary vein isolation for
atrial ﬁbrillation. Am J Cardiol 2003;91:83—5.
23] Vasamreddy CR, Lickfett L, Jayam VK, et al. Predictors of recur-
rence following catheter ablation of atrial ﬁbrillation using
an irrigated-tip ablation catheter. J Cardiovasc Electrophysiol
2004;15:692—7.
24] Lellouche N, Jaïs P, Nault I, et al. Early recurrences after
atrial ﬁbrillation ablation: prognostic value and effect of
early reablation. J Cardiovasc Electrophysiol 2008;19:599—
605.
25] Marchlinski FE, Callans D, Dixit S, Gerstenfeld EP, Rho R, Ren
JF, et al. Efﬁcacy and safety of targeted focal ablation versus
PV isolation assisted by magnetic electroanatomic mapping. J
Cardiovasc Electrophysiol 2003;14:358—65.
26] Schwartzman D, Ren JF, DevineWA, Callans DJ. Cardiac swelling
associated with linear radiofrequency ablation in the atrium.
J Interv Card Electrophysiol 2001;5:159—66.
27] Steel KE, Roman-Gonzalez J, O’Bryan 4th CL. Images in car-
diovascular medicine. Severe left atrial edema and heart
failure after atrial ﬁbrillation ablation. Circulation 2006;113:
e659.
28] Okada T, Yamada T, Murakami Y, et al. Prevalence and severity
of left atrial edema detected by electron beam tomogra-
phy early after pulmonary vein ablation. J Am Coll Cardiol
2007;49:1436—42.
29] Fenelon G, Brugada P. Delayed effects of radiofrequency
energy: mechanisms and clinical implications. Pacing Clin Elec-
trophysiol 1996;19:484—9.
30] Klein LS, Shih HT, Hackett FK, Zipes DP, Miles WM. Radiofre-
quency catheter ablation of ventricular tachycardia in
patients without structural heart disease. Circulation 1992;85:
1666—74.
31] Langberg JJ, Borganelli SM, Kalbﬂeisch SJ, Strickberger SA,
Calkins H, Morady F. Delayed effects of radiofrequency energy
on accessory atrioventricular connections. Pacing Clin Electro-
physiol 1993;16:1001—5.32] Koyama T, Tada H, Sekiguchi Y, et al. Prevention of atrial ﬁb-
rillation recurrence with corticosteroids after radiofrequency
catheter ablation: a randomized controlled trial. J Am Coll
Cardiol 2010;56:1463—72.
